tiprankstipranks
Trending News
More News >
Harvard Bioscience (HBIO)
NASDAQ:HBIO

Harvard Bioscience (HBIO) Price & Analysis

Compare
275 Followers

HBIO Stock Chart & Stats

$0.40
-$0.02(-0.93%)
At close: 4:00 PM EST
$0.40
-$0.02(-0.93%)

Bulls Say, Bears Say

Bulls Say
Backlog And Product DemandAn expanding backlog and strong demand for new products underpin a revenue guide that exceeded consensus, signaling sustained order momentum.
Operational Efficiency And ERP BenefitsAdjusted EBITDA exceeded estimates as expense discipline, a new ERP system, and a healthier consumables sales mix improved operational leverage.
Revenue And MarginsRevenue beat consensus and gross margins improved due to broad sales execution and financial discipline, supporting upside to profitability.
Bears Say
Government Funding RiskContinuation of a government shutdown and delayed NIH funding could push revenue toward the lower end of guidance, creating external funding risk for sales.
Guidance And Forecast RiskSustained disruption in public research funding could force guidance revisions and pressure expected profitability and valuation.
Revenue Timing And VisibilityDelays in federal research funding may postpone recognition of backlog-driven sales into later reporting periods, reducing near-term revenue visibility.

Harvard Bioscience News

HBIO FAQ

What was Harvard Bioscience’s price range in the past 12 months?
Harvard Bioscience lowest stock price was $0.28 and its highest was $1.43 in the past 12 months.
    What is Harvard Bioscience’s market cap?
    Harvard Bioscience’s market cap is $24.32M.
      When is Harvard Bioscience’s upcoming earnings report date?
      Harvard Bioscience’s upcoming earnings report date is Mar 12, 2026 which is in 26 days.
        How were Harvard Bioscience’s earnings last quarter?
        Harvard Bioscience released its earnings results on Nov 06, 2025. The company reported $0 earnings per share for the quarter, missing the consensus estimate of $0.005 by -$0.005.
          Is Harvard Bioscience overvalued?
          According to Wall Street analysts Harvard Bioscience’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Harvard Bioscience pay dividends?
            Harvard Bioscience does not currently pay dividends.
            What is Harvard Bioscience’s EPS estimate?
            Harvard Bioscience’s EPS estimate is 0.04.
              How many shares outstanding does Harvard Bioscience have?
              Harvard Bioscience has 44,719,894 shares outstanding.
                What happened to Harvard Bioscience’s price movement after its last earnings report?
                Harvard Bioscience reported an EPS of $0 in its last earnings report, missing expectations of $0.005. Following the earnings report the stock price went down -7.313%.
                  Which hedge fund is a major shareholder of Harvard Bioscience?
                  Currently, no hedge funds are holding shares in HBIO
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    Harvard Bioscience

                    Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

                    Harvard Bioscience (HBIO) Earnings & Revenues

                    HBIO Company Deck

                    HBIO Earnings Call

                    Q3 2025
                    0:00 / 0:00
                    Earnings Call Sentiment|Positive
                    The earnings call highlighted strong operational improvements, a significant increase in backlog and order growth, successful product launches, and positive cash flow management. However, these positives were somewhat offset by year-over-year revenue decline, challenges in the China market, and uncertainty due to the U.S. government shutdown affecting NIH funding. Overall, the company's efforts to enhance operational efficiency and increase product demand reflect a positive outlook despite some ongoing challenges.View all HBIO earnings summaries
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Retractable Technologies
                    EKSO BIONICS
                    Milestone Scientific
                    NexGel Inc

                    Ownership Overview

                    10.31%6.77%0.33%78.91%
                    10.31% Insiders
                    0.33% Other Institutional Investors
                    78.91% Public Companies and
                    Individual Investors
                    Popular Stocks